香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不引起本公司、其保薦人、獨家整體 協調人、顧問或承銷團成員在香港或任何其他司法管轄區必須進行發售活動的責任。本公司最終會 否進行任何發售仍屬未知之數； (c) 本文件或其任何補充、修訂或更換附頁的內容可能會亦可能不會在最後正式的上市文件內全部或部 分轉載； (d) 本申請版本並非最終的上市文件，本公司可能不時根據《香港聯合交易所有限公司證券上市規則》 作出更新或修訂； (e) 本文件並不構成向任何司法管轄區的公眾人士提呈出售任何證券的招股章程、發售通函、通告、通 函、小冊子或廣告，亦非邀請公眾人士提出認購或購買任何證券的要約，且不旨在邀請公眾提出認 購或購買任何證券的要約； (f) 本文件不應被視為誘使認購或購買任何 ...

Core Viewpoint - The company, Yuyantang, has submitted its prospectus to the Hong Kong Stock Exchange, with Zhuhai International and Guoyuan International acting as joint sponsors, focusing on a "full lifecycle diagnosis and treatment model" based on Traditional Chinese Medicine (TCM) principles [1] Group 1: Business Model - The company operates on a "preventive treatment" philosophy, covering four stages: "pre-disease, desire for disease, existing disease, and post-recovery," providing integrated personalized health solutions that include prevention, adjustment, treatment, and maintenance [1] - Yuyantang employs a strict model of "offline initial diagnosis and online follow-up," ensuring all patients complete diagnostic assessments at licensed offline institutions, while the online platform manages follow-ups, chronic disease care, and health management to ensure service continuity [1] Group 2: Market Position - According to a Frost & Sullivan report, Yuyantang ranks as the second-largest private chain TCM healthcare service provider in Northern China by total revenue from TCM outpatient services and clinics as of 2024, and it ranks first in revenue from medicinal pastes [1] - The company boasts the highest customer repurchase rate among private chain TCM healthcare service providers, achieving a repurchase rate of 81.1% for the nine months ending September 30, 2025 [1] Group 3: Infrastructure and Expertise - Yuyantang has established a network of 48 self-built and operated licensed medical institutions in Northern China, all managed through a unified cloud-based healthcare information system (HIS) for digital management [1] - The company offers personalized TCM prescriptions, including decoctions, pills, powders, and pastes, and possesses proprietary non-heritage pastes and several in-house developed formulations as protected therapeutic assets [1] - Yuyantang employs 292 full-time medical professionals, with a research committee comprising 98 experts, integrating knowledge from both internal medical teams and external research collaborators [1]

Group 1: Yuanji Food - Yuanji Food Group submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, aiming for a main board listing, with Huatai International and GF Securities as joint sponsors [3] - Established in 2017, Yuanji Food has become the largest Chinese and global fast-food enterprise, focusing on handmade dumplings and wontons, with 4,266 stores across China and Southeast Asia as of September 30, 2025 [3] - The gross merchandise value (GMV) for Yuanji Food's stores was 4.772 billion yuan in 2023 and 6.247 billion yuan in 2024, representing a year-on-year growth of 30.9% [3] - Revenue for Yuanji Food was 2.026 billion yuan in 2023 and 2.561 billion yuan in 2024, with a year-on-year growth of 26.4% [4] Group 2: Qian Dama - Qian Dama International Holdings submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, with CICC and Agricultural Bank of China International as joint sponsors [5] - Founded in 2014, Qian Dama focuses on providing fresh, high-quality products and a convenient shopping experience, leading the community fresh retail market in South China with a GMV of approximately 9.8 billion yuan in 2024 [5][6] - As of September 30, 2025, Qian Dama operated 2,938 community stores across 14 provinces and municipalities in China [6] - Revenue for Qian Dama was 11.744 billion yuan in 2023 and 11.787 billion yuan in 2024, with a gross margin of 10.2% in 2024 [7] Group 3: Big Pizza - Big Restaurant International Holdings submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with Bank of China International as the sole sponsor [8] - Established in 2002, Big Pizza operates 342 stores across 28 provinces and cities in China, with plans to open approximately 610 to 790 new stores from 2026 to 2028 [8][9] - The GMV for Big Pizza was 1.7 billion yuan in the first three quarters of 2025, ranking first among local pizza restaurants in China [9] - Revenue for Big Pizza was 944 million yuan in 2023 and 1.147 billion yuan in 2024, with a significant increase of 66.6% to 1.389 billion yuan in the first three quarters of 2025 [10] Group 4: Zeling Bio - Chengdu Zeling Biomedical Technology submitted its prospectus to the Hong Kong Stock Exchange on January 13, 2026, with Jefferies and CICC as joint sponsors [12] - Founded in 2019, Zeling Bio focuses on developing differentiated small molecule therapies for unmet medical needs in blood system diseases, tumors, and CNS diseases [12] - As of January 5, 2026, Zeling Bio has established a pipeline of eight proprietary assets, including two core products in Phase III clinical trials [12][13] Group 5: Exegenesis Bio - Exegenesis Bio Inc. submitted its prospectus to the Hong Kong Stock Exchange on January 14, 2026, with CCB International as the sole sponsor [15] - Founded in 2019, Exegenesis Bio specializes in gene therapy and oligonucleotide drugs, with a focus on innovative delivery systems [15][16] - The core candidate product EXG001-307 is a potential best-in-class therapy for spinal muscular atrophy (SMA) type 1, currently in the registration clinical trial phase [16] Group 6: Yuyuantang - Harbin Yuyuantang Traditional Chinese Medicine Clinic Group submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with 招银国际 and 国元国际 as joint sponsors [17] - Established in 2018, Yuyuantang provides a full lifecycle treatment model for traditional Chinese medicine, operating 48 licensed medical institutions in Northern China as of January 6, 2026 [17][18] - Revenue for Yuyuantang was 150 million yuan in 2023 and 215 million yuan in 2024, with a significant increase of 96.6% to 284 million yuan in the first three quarters of 2025 [18] Group 7: Laoxiangji - LXJ International Holdings updated its prospectus for the Hong Kong Stock Exchange, continuing its listing process with CICC and Guotai Junan as joint sponsors [19] - Founded in 2003, Laoxiangji operates 1,658 stores across 61 cities in China, with a market share of 0.9% in the Chinese fast-food industry [19][20] - Revenue for Laoxiangji was 4.528 billion yuan in 2022, 5.651 billion yuan in 2023, and 6.288 billion yuan in 2024, with a 10.9% increase to 4.578 billion yuan in the first eight months of 2025 [20][21] Group 8: Immvira Bioscience - Immvira Bioscience updated its prospectus for the Hong Kong Stock Exchange on January 14, 2026, with Citigroup and CICC as joint sponsors [22] - Immvira is a biotechnology company with a focus on oncolytic immunotherapy candidates and innovative engineered exosome therapeutic products [22] - The core product MVR-T3011 targets a wide range of solid tumors, including bladder cancer and head and neck squamous cell carcinoma [22]

Core Viewpoint - The article provides an overview of recent IPO activities in Hong Kong, the US, and A-shares, highlighting several companies that have submitted their prospectuses for listing on the Hong Kong Stock Exchange. Group 1: Yuanji Food - Yuanji Food Group Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, aiming for a main board listing, with Huatai International and GF Securities as joint sponsors [3] - Established in 2017, Yuanji Food has become the largest Chinese fast-food enterprise globally and the largest dumpling and wonton company in China, focusing on "handmade, freshly wrapped and cooked" products [3] - As of September 30, 2025, Yuanji Food operated 4,266 stores across China and Southeast Asia, with a GMV of 47.72 billion yuan in 2023 and 62.47 billion yuan in 2024, representing a year-on-year growth of 30.9% [4] Group 2: Qian Dama - Qian Dama International Holdings Limited submitted its prospectus to the Hong Kong Stock Exchange on January 12, 2026, with CICC and Agricultural Bank of China International as joint sponsors [6] - Founded in 2014, Qian Dama focuses on providing fresh, high-quality products and has pioneered the "discount day clearance" sales model, becoming the absolute leader in the community fresh food retail market in South China [6] - As of September 30, 2025, Qian Dama had 2,938 community stores across 14 provinces, with a GMV of 148 billion yuan in 2024 [7] Group 3: Big Pizza - Big Restaurant International Holdings Limited submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with Bank of China International as the sole sponsor [10] - Established in 2002, Big Pizza operates 342 stores across 28 provinces and cities in China, with plans to open approximately 610 to 790 new stores from 2026 to 2028 [10] - In the first three quarters of 2025, Big Pizza achieved a GMV of 17 billion yuan, ranking first among domestic pizza restaurants [10] Group 4: Zeling Bio - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 13, 2026, with Jefferies and CICC as joint sponsors [14] - Founded in 2019, Zeling Bio focuses on developing innovative small molecule therapies for unmet medical needs in blood system diseases, tumors, and CNS diseases [14] - As of January 5, 2026, Zeling Bio has established a pipeline of eight proprietary assets, including two core products in Phase 3 clinical trials [14] Group 5: Jia Yin Bio - Exegenesis Bio Inc. submitted its prospectus to the Hong Kong Stock Exchange on January 14, 2026, with Jianyin International as the sole sponsor [18] - Founded in 2019, Jia Yin Bio specializes in gene therapy and oligonucleotide drugs, with a focus on developing a diverse and scalable product pipeline [18] - The core candidate product EXG001-307 is a potential best-in-class therapy for spinal muscular atrophy (SMA) type 1, currently in the registration clinical trial phase [19] Group 6: Yu Yan Tang - Harbin Yu Yan Tang Traditional Chinese Medicine Clinic Group Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on January 16, 2026, with 招银国际 and 国元国际 as joint sponsors [21] - Established in 2018, Yu Yan Tang provides a full lifecycle of TCM medical services, operating a network of 48 licensed medical institutions in northern China [21] - The company ranked fifth among private chain TCM service providers in China by total revenue in 2024, with a customer repurchase rate of 81.1% in the first three quarters of 2025 [22] Group 7: Lao Xiang Ji - LXJ International Holdings Limited updated its prospectus to continue the listing process on the Hong Kong Stock Exchange, with CICC and Guotai Junan as joint sponsors [24] - Founded in 2003, Lao Xiang Ji operates 1,658 stores across 61 cities in China, with a market share of 0.9% in the Chinese fast-food industry [24] - The company reported revenues of 45.28 billion yuan in 2022, 56.51 billion yuan in 2023, and 62.88 billion yuan in 2024, with a 10.9% increase in revenue in the first eight months of 2025 [26]

Core Viewpoint - Harbin Yuyuantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance its market position in the traditional Chinese medicine sector [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyuantang's full lifecycle diagnosis and treatment model covers disease prevention, adjustment, treatment, and health maintenance, providing personalized and continuous health management services [2][7]. - The company has established a network of 48 self-operated licensed medical institutions in Northern China, utilizing a unified cloud-based medical information system for digital management [2][6]. Group 2: Market Position and Customer Loyalty - According to a report by Frost & Sullivan, Yuyuantang ranks second among private chain TCM medical service providers in Northern China by total revenue and first in revenue from medicinal pastes [1]. - The company's customer repurchase rate reached 81.1% as of September 30, 2025, indicating strong market recognition of its service value and efficacy [3]. Group 3: Product Development and Supply Chain - Yuyuantang adheres to the "one person, one prescription" principle, offering various personalized traditional Chinese medicine formulations, including decoctions, pills, powders, and pastes [4]. - The company has developed proprietary non-heritage pastes that enhance patient compliance and serve as key components in chronic disease management [4]. - Yuyuantang is focused on building a dedicated facility for producing traditional Chinese medicine pieces, ensuring supply chain security and quality control through vertical integration [6]. Group 4: Strategic Outlook - The company plans to expand its geographic footprint in provinces such as Shandong, Hebei, Henan, and Tianjin, while enhancing resource allocation and market influence [6]. - With the ongoing implementation of the "Healthy China 2030" initiative and various TCM revitalization policies, the market for TCM medical services is poised for systematic growth, aligning with the increasing demand for long-term health management [7].

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance patient care and capitalize on the growing demand for traditional Chinese medicine services in China [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyantang's "full lifecycle diagnosis and treatment model" covers the stages of "preventive care, disease management, treatment, and recovery," providing personalized health management solutions through modern TCM assessment tools and big data analysis [2][3]. - The company has established a network of 48 self-operated licensed medical institutions in northern China, utilizing a unified cloud-based medical information system for digital management [3]. Group 2: Product Offerings - Yuyantang adheres to the "one person, one prescription" principle, offering various personalized TCM formulations, including decoctions, pills, powders, and ointments, which enhance patient compliance and serve as key components in chronic disease management [4]. - The company has proprietary non-heritage ointments and several self-developed hospital formulations that are continuously refined based on clinical experience, forming a standardized and clinically validated foundation for its services [4]. Group 3: Talent and Team Structure - The company employs 292 full-time medical professionals, ensuring stable and continuous service quality, while its research committee consists of 98 experts, driving innovation and maintaining high standards in patient care [5]. Group 4: Supply Chain and Production Strategy - Yuyantang's core strategy includes building a dedicated facility for producing TCM raw materials, which enhances supply chain security and quality control from raw materials to final products [6]. - The company aims to expand its regional presence in provinces such as Shandong, Hebei, Henan, and Tianjin, while digitally transforming its production facilities to ensure quality assurance [6]. Group 5: Market Opportunities - The traditional Chinese medicine service market is experiencing systemic growth opportunities due to the "Healthy China 2030" initiative and various TCM revitalization policies, aligning with the increasing demand for long-term health management [7]. - Yuyantang's innovative service model and integrated operational ecosystem position it well for accelerated growth through its upcoming public listing, reflecting a shift in the private TCM sector towards standardized and sustainable high-quality development [7].

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, with CMB International and Guoyuan International serving as joint sponsors [1] Company Overview - Yuyantang's core service model is based on a "full lifecycle diagnosis and treatment" approach, integrating offline licensed medical institutions with a dedicated online platform to create a comprehensive TCM service system [1] - The model is founded on the TCM philosophy of "preventing disease before it occurs," systematically covering four stages: "pre-disease, desire for disease, already ill, and post-recovery" [1] Market Position - According to a Frost & Sullivan report, Yuyantang ranks second among private chain TCM medical service providers in Northern China based on total revenue from TCM clinics and outpatient services for 2024 [1] - The company ranks first nationwide in terms of revenue from medicinal pastes [1] - Yuyantang has the highest customer repurchase rate among private chain TCM medical service providers in 2024, reflecting strong patient trust [1] Industry Trends - The TCM industry is being driven towards standardization, chain development, and digital transformation by policies such as the "14th Five-Year Plan for TCM Development" [1] - Yuyantang has established a relatively mature compliance operation and standardization system, positioning itself to further consolidate its market position amid increasing industry concentration [1]

Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. (Yuyantang) is set to list on the Hong Kong Stock Exchange, aiming to expand its traditional Chinese medicine services through a fully integrated treatment model and a self-built network of licensed medical institutions [3][5]. Group 1: Company Overview - Yuyantang was established in 2018 and operates a network of 48 self-built licensed medical institutions in Northern China, ensuring standardized operations and consistent care quality [5]. - The company ranks fifth among private chain TCM service providers in China by total revenue and first in revenue from traditional Chinese medicine preparations [5]. - Yuyantang has a high customer loyalty rate, with a repurchase rate of 81.1% in the first three quarters of 2025 [5]. Group 2: Service Model and Offerings - The company follows a "one person, one prescription" principle, offering personalized TCM preparations, including decoctions, pills, powders, and ointments, enhancing patient compliance [6]. - Yuyantang has developed proprietary in-house formulations based on clinical experience, which are integral to its chronic disease management processes [6]. Group 3: Workforce and Innovation - As of January 6, 2026, Yuyantang employs 292 full-time medical professionals and has a research committee of 98 experts, driving innovation and improving patient care standards [7]. - The TCM service market in China is projected to grow from 659.9 billion yuan in 2019 to 1,020.16 billion yuan by 2024, with a compound annual growth rate of 10.1% expected until 2029 [7]. Group 4: Future Development Plans - Yuyantang plans to expand its geographic footprint in provinces like Shandong, Hebei, Henan, and Tianjin, focusing on self-built and self-operated models to enhance market penetration [8]. - The company aims to digitally transform its production facilities and strengthen its service and product value through standardized TCM services and backend product collaboration [8]. Group 5: Financial Performance - Yuyantang's revenue for 2023 and 2024 is projected at 150 million yuan and 215 million yuan, respectively, reflecting a year-on-year growth of 43.5% [8]. - For the first three quarters of 2025, revenue increased by 96.6% to 284 million yuan compared to the same period in 2024 [8]. - The adjusted net profit margins for 2023, 2024, and the first three quarters of 2025 are 13.7%, 12.6%, and 21.7%, respectively [9]. Group 6: IPO Fund Utilization - Approximately 33% of the IPO proceeds will be used to open new licensed medical institutions, while 24% will enhance production capacity [9]. - Other allocations include 10% for developing intelligent systems, 10% for brand enhancement, and 5% for optimizing TCM services, particularly in in-house formulations [9].

Core Viewpoint - The conference on the high-quality development path of Traditional Chinese Medicine (TCM) medical alliances was held in Guangzhou, emphasizing the importance of collaboration between educational institutions and healthcare providers to enhance TCM services and accessibility [1][4]. Group 1: Conference Highlights - The conference was organized by the World Federation of Chinese Medicine Societies and attended by leaders from various healthcare and educational institutions, focusing on the expansion of quality medical resources [1]. - Solidarity in TCM medical alliances was showcased, with Solidarity Hall announcing partnerships with 13 new high-level medical alliance units, including top hospitals and universities [1][2]. Group 2: Educational Initiatives - Solidarity Hall launched the "Rising Talent Scholarship" in collaboration with Guangzhou University of Chinese Medicine to support students in nursing and related fields, aiming to align educational outcomes with industry needs [2]. - A strategic cooperation agreement was signed with China Traditional Chinese Medicine News to promote TCM culture and share best practices in medical alliance construction [2]. Group 3: Expert Contributions - The conference featured high-level reports, including insights from the National Medical Insurance Administration on integrating TCM services into the insurance system, and presentations on innovative TCM techniques [3]. - The event marked a new phase in TCM medical alliance construction, focusing on consensus building and collaborative efforts for effective outcomes [4].

Core Insights - The conference on "Inheritance, Innovation, and Development" for the World Traditional Chinese Medicine Alliance was successfully held in Guangzhou, focusing on high-quality development paths for TCM medical alliances and promoting the expansion of quality medical resources [1] Group 1: Solidifying Medical Alliances - The company has established 13 new high-level medical alliance cooperation units since 2025, including top public hospitals and TCM universities, reflecting strong recognition of its business model and medical service capabilities [5] - The company has formed close medical alliance cooperation with over 40 public tertiary hospitals and TCM institutions, including deep collaborations with 9 of the top 20 TCM universities in the country [5] - The company aims to enhance accessibility to TCM services by integrating top expert resources into community healthcare through various methods, effectively breaking the time and space limitations of expert resources [5] Group 2: Talent Development - The launch of the "Rising Sun Talent Scholarship" aims to encourage outstanding students in nursing and related fields to engage in the TCM industry, facilitating seamless integration between educational institutions and industry needs [6][4] - The partnership between the company and Guangzhou University of Chinese Medicine focuses on building a multi-dimensional collaborative framework, including clinical internship bases and research on key disciplines [7] Group 3: Industry Collaboration - The company signed a strategic cooperation agreement with the authoritative media outlet, China Traditional Chinese Medicine News, to enhance the dissemination of TCM culture and share experiences in medical alliance construction [8] - This collaboration aims to create a high-quality content dissemination platform, promoting public awareness of TCM health concepts and sharing innovative achievements in medical alliances [8] Group 4: Conference Highlights - The conference featured multiple high-level thematic reports providing insights into medical alliance construction, including interpretations of national medical insurance policies and the promotion of standardized TCM techniques [10] - The successful hosting of this conference marks a new phase in the construction of TCM medical alliances, emphasizing consensus building, collaborative efforts, and practical outcomes [10]